Analysts forecast that Spark Therapeutics, Inc. (NASDAQ:ONCE) will report sales of $1.38 million for the current quarter, according to Zacks. Five analysts have provided estimates for Spark Therapeutics’ earnings, with estimates ranging from $1.27 million to $1.50 million. Spark Therapeutics posted sales of $1.30 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.2%. The business is scheduled to issue its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $1.38 million for the current fiscal year, with estimates ranging from $1.27 million to $25.80 million. For the next financial year, analysts expect that the business will report sales of $105.21 million per share, with estimates ranging from $33.18 million to $275.40 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same period in the previous year, the firm earned ($1.04) earnings per share. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis.

ONCE has been the subject of a number of recent research reports. Stifel Nicolaus reissued a “buy” rating and set a $76.00 price target on shares of Spark Therapeutics in a research report on Monday, April 10th. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 17th. Jefferies Group LLC initiated coverage on shares of Spark Therapeutics in a research report on Monday, July 10th. They set a “buy” rating and a $85.00 price target for the company. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $60.00 to $100.00 in a research report on Wednesday, August 2nd. Finally, UBS AG reissued a “buy” rating and set a $92.00 price target (up from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus price target of $82.27.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Spark Therapeutics, Inc. (NASDAQ:ONCE) Will Post Quarterly Sales of $1.38 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/brokerages-anticipate-spark-therapeutics-inc-nasdaqonce-will-post-quarterly-sales-of-1-38-million.html.

Spark Therapeutics (NASDAQ:ONCE) opened at 78.63 on Tuesday. The stock’s 50 day moving average is $63.15 and its 200 day moving average is $58.70. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $79.64. The stock’s market capitalization is $2.44 billion.

In other news, CEO Jeffrey D. Marrazzo sold 28,650 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total transaction of $2,292,286.50. Following the sale, the chief executive officer now owns 258,650 shares of the company’s stock, valued at approximately $20,694,586.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen W. Webster sold 2,337 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $71.12, for a total transaction of $166,207.44. Following the sale, the chief financial officer now directly owns 4,837 shares in the company, valued at approximately $344,007.44. The disclosure for this sale can be found here. Insiders have sold a total of 314,310 shares of company stock worth $21,866,838 in the last ninety days. Corporate insiders own 7.30% of the company’s stock.

Several large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its stake in shares of Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in shares of Spark Therapeutics during the first quarter worth approximately $227,000. KCG Holdings Inc. boosted its stake in shares of Spark Therapeutics by 9.4% in the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after buying an additional 538 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Spark Therapeutics by 4.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 8,204 shares of the biotechnology company’s stock worth $409,000 after buying an additional 320 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Spark Therapeutics by 16.8% in the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after buying an additional 1,286 shares during the last quarter. 88.95% of the stock is currently owned by institutional investors and hedge funds.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.